Clinical Trials on Non-CNS Malignancies in Finland
Total 596 results
-
Orion Corporation, Orion PharmaCompleted
-
Sigma-Tau Research, Inc.Dana-Farber Cancer Institute; Rhode Island HospitalCompletedSolid MalignanciesUnited States
-
Tampere University HospitalHelsinki University Central Hospital; Tampere University; University of Eastern... and other collaboratorsActive, not recruiting
-
Turku University HospitalEnrolling by invitationMultiple SclerosisFinland
-
Turku University HospitalActive, not recruitingMultiple SclerosisFinland
-
Turku University HospitalActive, not recruiting
-
Turku University HospitalEnrolling by invitationMultiple SclerosisFinland
-
Turku University HospitalRecruiting
-
Helsinki University Central HospitalEnrolling by invitationNon-Alcoholic Fatty Liver DiseaseFinland
-
medac GmbHCompletedHematological MalignanciesGermany, Finland, Poland, Sweden
-
Helsinki University Central HospitalRecruitingSolid Tumor | Advanced Cancer | Haematological MalignancyFinland
-
University of Eastern FinlandKuopio University Hospital; Academisch Medisch Centrum - Universiteit van Amsterdam... and other collaboratorsCompletedExercise | Non-Alcoholic Fatty Liver Disease | Gastrointestinal MicrobiomeFinland
-
Turku University HospitalCompletedMultiple SclerosisFinland
-
University of TurkuUnknownColecalciferol as an Add-on Treatment to Interferon-beta-1b for Treatment of Multiple Sclerosis (MS)Multiple SclerosisFinland
-
Turku University HospitalActive, not recruitingMultiple SclerosisFinland
-
Precision BioSciences, Inc.RecruitingHematologic Malignancy | CD19 Expressing MalignanciesUnited States
-
Northwell HealthCompletedMediastinal Lymphadenopathy | Lung MalignanciesUnited States
-
BayerNovartis Pharmaceuticals; Biogen; EPID Research; Merck Serono Europe LtdCompleted
-
Turku University HospitalCompletedMultiple Sclerosis | Multiple Sclerosis, Chronic Progressive | Multiple Sclerosis, Relapsing-RemittingFinland
-
Helsinki University Central HospitalInstitute for Molecular MedicineUnknown
-
BayerBiogen Netherlands B.V; Novartis Europharm Limited; Merck Europe B.V.Not yet recruitingMultiple Sclerosis (MS)Sweden, Finland
-
BiogenCompletedRelapsing-Remitting Multiple SclerosisFinland
-
Kuopio University HospitalCompletedRelapse-remitting Multiple SclerosisFinland
-
University of OuluOulu University HospitalCompleted
-
Finnish MS SocietySeinajoki Central Hospital; Social Insurance Institution, Finland; Tampere University...Completed
-
Rhode Island HospitalUnknownSolid Tumors | Hematological MalignanciesUnited States
-
Regeneron PharmaceuticalsSanofiCompletedMalignanciesUnited States, Korea, Republic of, Australia, Ireland, United Kingdom
-
Marja-Riitta TaskinenGöteborg UniversityEnrolling by invitationInsulin Resistance | Non-alcoholic Fatty Liver | Atherogenic DyslipidemiaFinland, Sweden
-
Turku University HospitalEnrolling by invitationMelanoma | Acute Myeloid Leukemia | Non Small Cell Lung CancerFinland
-
AstraZenecaCompletedNon-Metastatic Prostate CancerFinland
-
Hoffmann-La RocheCompletedNon-Small Cell Lung CancerFinland
-
BayerCompletedMultiple SclerosisGermany, Austria, United Kingdom, Israel, Belgium, Finland
-
Inland Norway University of Applied SciencesCompletedHeat-suit Endurance Training | Non-heat-suit Endurance TrainingNorway
-
University of Eastern FinlandCompletedQuality of Life | Fatigue | Physical Activity | Relapsing Remitting Multiple SclerosisFinland
-
Turku University HospitalCompletedLymphoma | Lymphoma, Non-Hodgkin | Hodgkin DiseaseFinland
-
Finnish Lung Cancer GroupRoche Pharma AGCompleted
-
AstraZenecaTerminatedSubjects With Resectable Local or Locally Advanced, Non-Metastatic (T2-T4, N0-N3, M0; Stages II and III) and Histologically-Confirmed Intestinal GCFinland
-
BioCis Pharma LtdTurku University Hospital; FinnMedi Oy; Tampere University HospitalCompletedCis-urocanic Acid (Cis-UCA) in Patients With Primary or Recurrent Non-muscle Invasive Bladder CancerNon-muscle Invasive Bladder CancerFinland
-
Cynosure, Inc.CompletedNon-invasive LipolysisUnited States
-
Oslo University HospitalAstraZenecaActive, not recruitingCancer | NSCLC | Non Small Cell Lung Cancer | NSCLC, Stage III | Non Small Cell Lung Cancer Stage IIINorway, Finland, Lithuania, Estonia
-
Oslo University HospitalAarhus University Hospital; Hoffmann-La RocheRecruitingLymphoma, FollicularNorway, Finland
-
GuerbetCompletedBlood Brain Barrier Defect | CNS LesionKorea, Republic of, United States, Czechia, Italy, Belgium, Poland, Hungary, Mexico
-
SanofiCompletedMultiple SclerosisUnited States, France, Canada, Germany, Spain, Finland, Norway
-
Regeneron PharmaceuticalsSanofiCompletedAdvanced Cancer | Advanced MalignanciesUnited States, Spain, Australia
-
US Department of Veterans AffairsTerminated
-
Shanghai Junshi Bioscience Co., Ltd.Iqvia Pty Ltd; TopAlliance Biosciences, Inc.Active, not recruitingAdvanced MalignanciesUnited States
-
Brown UniversityBristol-Myers SquibbRecruitingNon Small Cell Lung CancerUnited States
-
Brown UniversityLifespanActive, not recruitingStage III Non-small-cell Lung CancerUnited States
-
US Department of Veterans AffairsCompletedMultiple SclerosisUnited States
-
The Miriam HospitalNational Heart, Lung, and Blood Institute (NHLBI)Completed